Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Deepak L Bhatt (Brigham and Women's Hospital, Boston, MA, US) discuss the results and implications of the SCORED trial. Dr Van Spall asks about the change the original endpoints of the trial in light of the evolving knowledge on the SGLT2i class and the impact of the COVID19 pandemic. Dr Bhatt and Dr Van Spall reviews the patient population, results and the adverse events of the study. Dr Bhatt shares the lessons of the trial and they talk about how Sotagliflozin, a GLP1 and GLP2 inhibitor, could fit into medication regimens. 
 

Recorded remotely from Hamilton and Boston, 2020.

Recording Editor: Natascha Wienand
Editor: Mirjam Boros